The use of Mexidol in intensive therapy of acute severe ischemic stroke

Seryogin V.I., Dronova T.V.

GBU RO "Skopinskaya Central District Hospital", Ryazan Region, Russia

The purpose of the study is to study the effectiveness and safety of the early use of Mexidol in the acute period of severe ischemic stroke (AI). Material and methods. The study included 112 patients aged 35–85 years with severe AI. Patients were divided into two groups comparable by gender and age. The main group (n = 59) received Mexidol at a dose of 400 mg per day intravenously for 10 days and basic therapy. The comparison group (n = 53) received only basic therapy. Results and discussion. In the main group, the share of favorable outcomes in severe AI in both early and delayed treatment (on the Rankin scale) was higher than in the comparison group, and mortality is significantly lower. The results of the study showed that the use of Mexidol increases the effectiveness of therapy. The drug can be recommended for the treatment of patients with severe carotid AI.

Key words: heavy ischemic stroke, Mexidol, treatment.